{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CI","limit":50},"count":50,"signals":[{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":32,"context":"e internal review of executive and employee incentive compensation programs is conducted to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to and discussed by the Committee each year. The review analyzes: compensation governance processes, including general design philosophy and","filed_date":"2026-03-13","accession":"0001739940-26-000023","full_text":"https://origin.rootz.global/static/filing/0001739940-26-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":24,"context":"ance is achievedNo overlap between short- and long-term metrics, and incentives use both absolute and relative metrics | | | | | | | Compensation Benchmarking Committee review of compensation targets Named executive officer total target compensation within the competitive range of the market median | | | | | | | Strong Compensation GovernanceRobust clawback, anti-hedging, and anti-pledging policies Annual compensation r","filed_date":"2026-03-13","accession":"0001739940-26-000023","full_text":"https://origin.rootz.global/static/filing/0001739940-26-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ing a sustainable advantage through data, insights and digital innovation. We drive efficiencies, improve sentiment and create market differentiation, while accelerating our path toward personalized, AI-driven solutions for customers, clients and providers. We deliver digital products and features at scale with a commitment to security, resiliency and compliance. Our digital strategy also focuses on the drive from","filed_date":"2026-02-26","accession":"0001739940-26-000006","full_text":"https://origin.rootz.global/static/filing/0001739940-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":111,"context":"mine possible future money laundering risk.Item 1A. RISK FACTORSAs a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2026-02-26","accession":"0001739940-26-000006","full_text":"https://origin.rootz.global/static/filing/0001739940-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":26,"context":"prehensive review of executive and employee incentive compensation programs is conducted to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to, and discussed by, the Committee each year. The review analyzes: compensation governance processes, including general design philosophy an","filed_date":"2025-03-14","accession":"0001739940-25-000015","full_text":"https://origin.rootz.global/static/filing/0001739940-25-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":23,"context":"mance is achievedNo overlap between short- and long-term metrics, and incentives use both absolute and relative metrics | | | | | | | Benchmarked Compensation Committee review of compensation targets Named executive officer total target compensation within the competitive range of the market median | | | | | | | Strong Compensation GovernanceRobust clawback, anti-hedging, and anti-pledging policies Annual compensation r","filed_date":"2025-03-14","accession":"0001739940-25-000015","full_text":"https://origin.rootz.global/static/filing/0001739940-25-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":110,"context":"ine possible future money laundering risk.Item 1A. RISK FACTORS As a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2025-02-27","accession":"0001739940-25-000009","full_text":"https://origin.rootz.global/static/filing/0001739940-25-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":16,"context":"eans margin stock within the meaning of Regulation U. Material Acquisition means any Acquisition the total consideration for which is equal to or greater than $250,000,000. Material Adverse Change or Material Adverse Effect means a material adverse change in or a material adverse effect on (a) the business, financial condition, operations or properties of the Company and its Subsidiaries, taken as a whole, or (b) the le","filed_date":"2024-04-26","accession":"0000950159-24-000130","full_text":"https://origin.rootz.global/static/filing/0000950159-24-000130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":24,"context":"prehensive review of executive and employee incentive compensation programs is conducted to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to, and discussed by, the Committee each year. The review analyzes: compensation governance processes, including general design philosophy an","filed_date":"2024-03-15","accession":"0001739940-24-000010","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ortium (NBIC) listed our company among the 2023 \"Best-of-the-Best\" Corporations for Inclusion.Our Commitment to GovernanceIn June 2023, Dr. Philip Ozuah, President and CEO of Montefiore Medicine, was appointed as a new independent director to our Board of Directors. Dr. Ozuah, who has 32 years of experience in medicine, adds to the deep expertise and diverse backgrounds of our board. His national reputation as a leader in value-based c","filed_date":"2024-03-15","accession":"0001739940-24-000010","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"management of our PBM clients' drug costs through operating efficiencies and generic substitutions. The Home Delivery Pharmacy operations consist of thirteen licensed pharmacies, including four fulfillment pharmacies. Our fulfillment pharmacies are located in Arizona, Indiana, Missouri and New Jersey. Specialty and Care Services Specialty Pharmacy. Specialty medications are primarily characterized a","filed_date":"2024-02-29","accession":"0001739940-24-000005","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":114,"context":"tial penalties in multiple jurisdictions.29Item 1A. RISK FACTORSAs a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2024-02-29","accession":"0001739940-24-000005","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":16,"context":"eans margin stock within the meaning of Regulation U. Material Acquisition means any Acquisition the total consideration for which is equal to or greater than $250,000,000. Material Adverse Change or Material Adverse Effect means a material adverse change in or a material adverse effect on (a) the business, financial condition, operations or properties of the Company and its Subsidiaries, taken as a whole, or (b) the le","filed_date":"2023-04-28","accession":"0000950159-23-000155","full_text":"https://origin.rootz.global/static/filing/0000950159-23-000155.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":21,"context":"prehensive review of executive and employee incentive compensation programs is conducted to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to, and discussed by, the Committee each year. The review analyzes: |  |  compensation governance processes, including general design philoso","filed_date":"2023-03-17","accession":"0001140361-23-012300","full_text":"https://origin.rootz.global/static/filing/0001140361-23-012300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":28,"context":"trics, and incentives use both absolute and relative metrics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | |  |  |  |  Benchmarked Compensation  Committee review of compensation targets  Named executive officer total direct compensation within the competitive range of the market median |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | |  |  |  |  Minimize Compensation Risk Robust stock ownership gu","filed_date":"2023-03-17","accession":"0001140361-23-012300","full_text":"https://origin.rootz.global/static/filing/0001140361-23-012300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":67,"context":"rruption laws to which we are subject. 32 Item 1A. RISK FACTORS As a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2023-02-23","accession":"0001739940-23-000008","full_text":"https://origin.rootz.global/static/filing/0001739940-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":17,"context":"eans margin stock within the meaning of Regulation U. Material Acquisition means any Acquisition the total consideration for which is equal to or greater than $250,000,000. Material Adverse Change or Material Adverse Effect means a material adverse change in or a material adverse effect on (a) the business, financial condition, operations or properties of the Company and its Subsidiaries, taken as a whole, or (b) the le","filed_date":"2022-04-29","accession":"0000950159-22-000102","full_text":"https://origin.rootz.global/static/filing/0000950159-22-000102.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":15,"context":"nducts a comprehensive review of executive and employee incentive compensation programs  to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to, and discussed by, the Committee each year. The review analyzes:  |  |  compensation governance processes, including general design philos","filed_date":"2022-03-18","accession":"0001140361-22-010160","full_text":"https://origin.rootz.global/static/filing/0001140361-22-010160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":20,"context":"retired from the Board at the end of the year. During his tenure, we benefited from Ikes many contributions and counsel, and share his optimism for our future. With Ikes retirement, Eric Wiseman was appointed to Lead Independent Director, and looks forward to continuing to serve and deliver on our mission.  Annual Meeting of Shareholders  On behalf of the Cigna Corporation Board of Directors, we invite you to attend our 2022 Annual M","filed_date":"2022-03-18","accession":"0001140361-22-010160","full_text":"https://origin.rootz.global/static/filing/0001140361-22-010160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ipts Pharmacy, Accredo and our retail networks by integrating retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management and pharmacy fulfillment services. We administer payments to retail networks and bill benefits costs to our clients through our end-to-end adjudication services. Drug Utilization Review program. When pharmacies submit cla","filed_date":"2022-02-24","accession":"0001739940-22-000007","full_text":"https://origin.rootz.global/static/filing/0001739940-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":54,"context":"laws to which we are subject. 32 Item 1A. RISK FACTORS As a large global health services company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2022-02-24","accession":"0001739940-22-000007","full_text":"https://origin.rootz.global/static/filing/0001739940-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":15,"context":"alize our plans following the completion of the divestiture. See Note 15 for further information regarding our organizational efficiency charge. Information about Segments As previously disclosed, we entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in seven countries to Chubb INA Holdings, Inc. (\"Chubb\") for $5.75 billion cash (the \"Chubb Transaction\"). Subject to a","filed_date":"2022-02-24","accession":"0001739940-22-000007","full_text":"https://origin.rootz.global/static/filing/0001739940-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":16,"context":"eans margin stock within the meaning of Regulation U. Material Acquisition means any Acquisition the total consideration for which is equal to or greater than $250,000,000. Material Adverse Change or Material Adverse Effect means a material adverse change in or a material adverse effect on (a) the business, financial condition, operations or properties of the Company and its Subsidiaries, taken as a whole, or (b) the le","filed_date":"2021-04-30","accession":"0001140361-21-015041","full_text":"https://origin.rootz.global/static/filing/0001140361-21-015041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"tock fund and several other funds selected from those offered to all Cigna employees under the Cigna 401(k) Plan. Directors may elect to receive payments under the Deferral Plan in a lump sum or installments. Lump sum payments are made, or payment installments begin, in January of the year following a directors separation from service.  Stock Ownership Guidelines  Cigna requires directors to maintain","filed_date":"2021-03-19","accession":"0001140361-21-009343","full_text":"https://origin.rootz.global/static/filing/0001140361-21-009343.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":24,"context":"tent with this practice and SEC rules, we are asking you to approve the following advisory resolution:  Resolved, that the shareholders approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys Proxy Statement for the 2021 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compen","filed_date":"2021-03-19","accession":"0001140361-21-009343","full_text":"https://origin.rootz.global/static/filing/0001140361-21-009343.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ipts Pharmacy, Accredo and our retail networks by integrating retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management and pharmacy fulfillment services. We administer payments to retail networks and bill benefits costs to our clients through our end-to-end adjudication services. Drug Utilization Review program: When pharmacies submit cla","filed_date":"2021-02-25","accession":"0001739940-21-000007","full_text":"https://origin.rootz.global/static/filing/0001739940-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":50,"context":"laws to which we are subject. 33 Item 1A. RISK FACTORS As a large global health service company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2021-02-25","accession":"0001739940-21-000007","full_text":"https://origin.rootz.global/static/filing/0001739940-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":13,"context":"eans margin stock within the meaning of Regulation U. Material Acquisition means any Acquisition the total consideration for which is equal to or greater than $250,000,000. Material Adverse Change or Material Adverse Effect means a material adverse change in or a material adverse effect on (a) the business, financial condition, operations or properties of the Company and its Subsidiaries, taken as a whole, or (b) the le","filed_date":"2020-04-03","accession":"0000950159-20-000089","full_text":"https://origin.rootz.global/static/filing/0000950159-20-000089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":22,"context":"tent with this practice and SEC rules, we are asking you to approve the following advisory resolution:  Resolved, that the shareholders approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys Proxy Statement for the 2020 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compen","filed_date":"2020-03-13","accession":"0001140361-20-005769","full_text":"https://origin.rootz.global/static/filing/0001140361-20-005769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":45,"context":"e of Contents](#TableOfContents) Item 1A. RISK FACTORS  As a large global health service company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2020-02-27","accession":"0001739940-20-000006","full_text":"https://origin.rootz.global/static/filing/0001739940-20-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rently serves as a director and did not receive payment for service as a director. There is no retainer for service on the Executive Committee. All retainer payments are made in equal, quarterly installments.  |  RETAINER TYPE |  ANNUAL AMOUNT |  METHOD OF PAYMENT |  | |  Board (other than the Chairman of the Board) |  $ |  180,000 |  |  Cigna common stock |  | |  $ |  95,000 |  |  Cash |  | |  Chair","filed_date":"2019-03-15","accession":"0001140361-19-005025","full_text":"https://origin.rootz.global/static/filing/0001140361-19-005025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":73,"context":"Officer conducts a comprehensive review of executive and employee compensation programs to determine whether incentive compensation plans are likely to promote risk-taking behavior that could have a material adverse effect on the Company. The findings of this review are presented to, and discussed by, the Committee in February of each year. The review analyzes:  |  |  |  compensation governance processes, including gen","filed_date":"2019-03-15","accession":"0001140361-19-005025","full_text":"https://origin.rootz.global/static/filing/0001140361-19-005025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":100,"match_count":26,"context":"|  No payment of dividends on unvested shares. |  |  | |  |  |  |  |  | |  |  | |  Emphasis on Performance Based Compensation |  | |  |  | |  The pay mix for the Chief Executive Officer and the other named executive officers (NEOs) during 2018 reflects our executive compensation philosophy that emphasizes performance-based compensation over fixed compensation. As illustrated in the charts below, performance-based compen","filed_date":"2019-03-15","accession":"0001140361-19-005025","full_text":"https://origin.rootz.global/static/filing/0001140361-19-005025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"M business beginning December 21, 2018 as well as Cigna's legacy home delivery operations that offer high quality, efficient, and cost-effective mail order, telephone, and on-line pharmaceutical fulfillment services. In 2018, Health Services reported adjusted revenues of $6.6 billion and pre-tax adjusted income from operations of $380 million, including 11 days of Express Scripts results.  |  |  |  |","filed_date":"2019-02-28","accession":"0001047469-19-000792","full_text":"https://origin.rootz.global/static/filing/0001047469-19-000792.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":100,"match_count":43,"context":"TEM 1A. Risk Factors  **** |  ITEM 1A. Risk Factors |  | *As a large global health service company operating in a complex industry, we encounter a variety of risks and uncertainties that could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, toget","filed_date":"2019-02-28","accession":"0001047469-19-000792","full_text":"https://origin.rootz.global/static/filing/0001047469-19-000792.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"his Supplemental Indenture on the date hereof. -2- \"Interest Payment Date\" when used with respect to any Senior Notes, means the date specified in such Senior Notes as the fixed date on which an installment of interest is due and payable. \"Mandatorily Redeemable Notes\" means the 18-Month Floating Rate Notes, the 2-Year Fixed Rate Notes, the 3-Year Floating Rate Notes, the 3-Year Fixed Rate Notes, the","filed_date":"2018-09-21","accession":"0000950159-18-000404","full_text":"https://origin.rootz.global/static/filing/0000950159-18-000404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"model approval and governance process for review of AI models in use or in development across the enterprise.We also have established comprehensive governance processes for new capabilities, such as generative AI (\"Gen AI\"). Our AI Center of Enablement (AI COE) expands on EMG and brings together individuals from across our technology, privacy, data governance, security, legal, compliance, marketing, and other","filed_date":"2025-03-14","accession":"0001739940-25-000015","full_text":"https://origin.rootz.global/static/filing/0001739940-25-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"e medications and unrestricted telephone access to customer care advocates and specially trained pharmacists. The Home Delivery Pharmacy operations consist of 13 licensed pharmacies, including 4 fulfillment pharmacies. Our fulfillment pharmacies are located in Arizona, Indiana, Missouri and New Jersey.Specialty and Care ServicesSpecialty Pharmacy. Specialty medications are primarily characterized as","filed_date":"2025-02-27","accession":"0001739940-25-000009","full_text":"https://origin.rootz.global/static/filing/0001739940-25-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"al other funds selected from those offered to all employees of The Cigna Group under The Cigna Group 401(k) Plan. Directors may elect to receive payments under the Deferral Plan in a lump sum or installments. Lump sum payments are made, or payment installments begin, in January of the year following a directors separation from service.  | | | 50 | 2024 Notice of Annual Meeting of Shareholders and Pro","filed_date":"2024-03-15","accession":"0001739940-24-000010","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ipts Pharmacy, Accredo and our retail networks by integrating retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management and pharmacy fulfillment services. We administer payments to retail networks and bill benefits costs to our clients through our end-to-end adjudication services. Drug Utilization Review Program. When pharmacies submit cla","filed_date":"2023-02-23","accession":"0001739940-23-000008","full_text":"https://origin.rootz.global/static/filing/0001739940-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"tock fund and several other funds selected from those offered to all Cigna employees under the Cigna 401(k) Plan. Directors may elect to receive payments under the Deferral Plan in a lump sum or installments. Lump sum payments are made, or payment installments begin, in January of the year following a directors separation from service.  **Stock Ownership Guidelines** Cigna requires directors to maint","filed_date":"2020-03-13","accession":"0001140361-20-005769","full_text":"https://origin.rootz.global/static/filing/0001140361-20-005769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"s Net Promoter Score, or NPS. Transparency: We committed to greater transparency by publishing our first Customer Transparency Report. We also introduced Clearity, a copay-only health plan leveraging AI-powered tools for transparency and for more personalized and informed decision-making. 2025 Performance and Accountability Our strong financial results in 2025 are a direct reflection of the meaningful value we c","filed_date":"2026-03-13","accession":"0001739940-26-000023","full_text":"https://origin.rootz.global/static/filing/0001739940-26-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":88,"match_count":11,"context":"e related liabilities, acceleration of cash proceeds from the accounts receivable factoring facility, lower income tax payments and higher CMS Part D annual settlement.Investing activitiesThe Company invested $2.7 billion in VillageMD in 2023. This, combined with the absence of the net $4.9 billion proceeds received from the Chubb transaction in 2022, resulted in an increase in cash used in investing activities.Financ","filed_date":"2024-02-29","accession":"0001739940-24-000005","full_text":"https://origin.rootz.global/static/filing/0001739940-24-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"tock fund and several other funds selected from those offered to all Cigna employees under the Cigna 401(k) Plan. Directors may elect to receive payments under the Deferral Plan in a lump sum or installments. Lump sum payments are made, or payment installments begin, in January of the year following a directors separation from service.  Stock Ownership Guidelines  Cigna requires directors to maintain","filed_date":"2022-03-18","accession":"0001140361-22-010160","full_text":"https://origin.rootz.global/static/filing/0001140361-22-010160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":88,"match_count":11,"context":"s chief financial officer of Cigna Corporation | | |  | | Matt Manders assumes leadership of government business as president, government and solutions of Cigna Corporation | | |  | | Everett Neville promoted to executive vice president, strategy and business development of Cigna Corporation | | |  | | Aparna Abburi promoted to president, Medicare | | |  | | Amy Bricker promoted to president, Express Scripts | | ** ** **BLOOMFIELD,","filed_date":"2020-12-10","accession":"0000950159-20-000273","full_text":"https://origin.rootz.global/static/filing/0000950159-20-000273.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":88,"match_count":11,"context":"ependent contractor or third party employee is not eligible for severance benefits even if such classification is modified retroactively. | 3 | | | | | **Covered Termination** -- a Covered Executives Separation from Service that is designated by the Plan Administrator as (i) an Involuntary Termination or (ii) a Change of Control Termination. The Plan Administrator shall determine whether a particular Separation","filed_date":"2020-10-30","accession":"0000950159-20-000231","full_text":"https://origin.rootz.global/static/filing/0000950159-20-000231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"strategic_event","strength":80,"match_count":10,"context":"we serve.  VillageMD. As of December 31, 2022, the Company had a commitment to become a minority owner in VillageMD by investing up to $2.7 billion in VillageMD preferred equity. In January 2023, we invested $2.5 billion of the $2.7 billion. VillageMD is an independent primary care group committed to offering high-quality, accessible primary care options for communities across the country through Village Medical. Vil","filed_date":"2023-02-23","accession":"0001739940-23-000008","full_text":"https://origin.rootz.global/static/filing/0001739940-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":73,"match_count":6,"context":"outlook include cash projections that may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the \"Risk Factors\" section of our 2022 Form 10-K. Though we believe we have adequate sources of liquidity, significant disruption or v","filed_date":"2023-11-02","accession":"0001739940-23-000025","full_text":"https://origin.rootz.global/static/filing/0001739940-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":73,"match_count":6,"context":"outlook include cash projections that may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the \"Risk Factors\" section of our 2021 Form 10-K. Though we believe we have adequate sources of liquidity, significant disruption or v","filed_date":"2022-11-03","accession":"0001739940-22-000025","full_text":"https://origin.rootz.global/static/filing/0001739940-22-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CI","company":"Cigna Group","exchange":"NYSE","sector":"Hospital & Medical Service Plans","signal_type":"risk_factor","strength":73,"match_count":6,"context":"outlook include cash projections that may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the \"Risk Factors\" section of our 2020 Form 10-K. Though we believe we have adequate sources of liquidity, significant disruption or v","filed_date":"2021-11-04","accession":"0001739940-21-000024","full_text":"https://origin.rootz.global/static/filing/0001739940-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"65993ace02a8b68760d905b8e6d084967cf7a601597ee285501ae1fc06606c6c","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"5944414be151185e136afe8ec572df08dcc665d8edd6fe13549ef988562a569f","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":1,"hourly_limit":500,"remaining":499,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}